Acutaas Chemicals Ltd
ACUTAASBSE 543349PharmaceuticalsMkt cap ₹26,160 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹330 Cr
YoY +59.1%QoQ -23.8%
Net profit · Q1 FY27
₹74.99 Cr
YoY +70.4%QoQ -44.2%
Net margin · Q1 FY27
22.8%
+1.5 pts vs Q1 FY26
Net profit · FY26
₹356 Cr
YoY +122.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 330 | 433 | 393 | 306 | 207 | +59.1% |
| Other income | 1.80 | 11.11 | 4.70 | 9.84 | 15.94 | -88.7% |
| Total income | 331 | 444 | 398 | 316 | 223 | +48.5% |
| Profit before tax | 104 | 184 | 145 | 96.18 | 58.08 | +78.9% |
| Tax | 28.92 | 49.52 | 38.45 | 24.32 | 14.07 | +105.5% |
| Net profit | 74.99 | 134 | 106 | 71.86 | 44.01 | +70.4% |
| Net margin | 22.8% | 31.0% | 27.0% | 23.5% | 21.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 1,339 | 1,007 | 717 | 617 | 520 | +33.0% |
| Other income | 41.59 | 16.93 | 7.49 | 4.32 | 2.76 | +145.7% |
| Total income | 1,381 | 1,024 | 725 | 621 | 523 | +34.9% |
| Profit before tax | 483 | 216 | 81.90 | 112 | 91.45 | +123.3% |
| Tax | 126 | 55.74 | 33.19 | 28.88 | 19.50 | +126.7% |
| Net profit | 356 | 160 | 48.71 | 83.29 | 71.95 | +122.1% |
| Net margin | 26.6% | 15.9% | 6.8% | 13.5% | 13.8% |
BIC's take
We haven't covered Acutaas Chemicals Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:02 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.